Molecular Markers for Novel Therapeutic Strategies in Pancreatic Endocrine Tumors

Overview

Journal Pancreas

Specialty Gastroenterology

Date 2012 Dec 6

PMID 23211371

Citations 21

Authors

Judith A Gilbert

Laura J Adhikari

Ricardo V Lloyd

Thorvardur R Halfdanarson

Michael H Muders

Matthew M Ames

Affiliations

Soon will be listed here.

Abstract

Objectives: Pancreatic endocrine tumors (PETs) share numerous features with gastrointestinal neuroendocrine (carcinoid) tumors. Targets of novel therapeutic strategies previously assessed in carcinoid tumors were analyzed in PETs (44 cases).

Methods: Activating mutations in EGFR, KIT, and PDGFRA and nonresponse mutations in KRAS were evaluated. Copy number of EGFR and HER-2/neu was quantified by fluorescence in situ hybridization. Expression of EGFR, PDGFRA, VEGFR1, TGFBR1, Hsp90, SSTR2A, SSTR5, IGF1R, mTOR, and MGMT was measured immunohistochemically.

Results: Elevated EGFR copy number was found in 38% of cases but no KRAS nonresponse mutations. VEGFR1, TGFBR1, PDGFRA, SSTR5, SSTR2A, and IGF1R exhibited the highest levels of expression in the largest percentages of PETs.Anticancer drugs BMS-754807 (selective for IGF1R/IR), 17-(allylamino)-17-demethoxygeldanamycin (17-AAG, targeting Hsp90), and axitinib (directed toward VEGFR1-3/PDGFRA-B/KIT) induced growth inhibition of human QGP-1 PET cells with IC50 values (nM) of 273, 723, and 743, respectively. At growth-inhibiting concentrations, BMS-754807 inhibited IGF1R phosphorylation; 17-AAG induced loss of EGFR, IGF1R, and VEGFR2; and axitinib increased p21(CDKN1A) expression without inhibiting VEGFR2 phosphorylation.

Conclusions: Results encourage further research into multidrug strategies incorporating inhibitors targeting IGF1R or Hsp90 and into studies of axitinib combined with conventional chemotherapeutics toxic to tumor cells in persistent growth arrest.

Citing Articles

Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments.

Richter S, Steenblock C, Fischer A, Lemm S, Ziegler C, Bechmann N Theranostics. 2024; 14(1):17-32.

PMID: 38164150 PMC: 10750207. DOI: 10.7150/thno.87345.

p21 Protein Outperforms Clinico-pathological Criteria in Predicting Liver Metastases in Pancreatic Endocrine Tumors.

Nasir A, Ahmed M, Saller J, Henderson-Jackson E, Malafa M, Yeatman T Cancer Genomics Proteomics. 2023; 20(6):522-530.

PMID: 37889062 PMC: 10614061. DOI: 10.21873/cgp.20402.

A systems biology approach to define mechanisms, phenotypes, and drivers in PanNETs with a personalized perspective.

Werle S, Ikonomi N, Lausser L, Kestler A, Weidner F, Schwab J NPJ Syst Biol Appl. 2023; 9(1):22.

PMID: 37270586 PMC: 10239456. DOI: 10.1038/s41540-023-00283-8.

Epigenetic reprogramming in pancreatic premalignancy and clinical implications.

Zhang W, Jiang T, Xie K Front Oncol. 2023; 13:1024151.

PMID: 36874143 PMC: 9978013. DOI: 10.3389/fonc.2023.1024151.

Expression and methylation status of MMR and MGMT in well-differentiated pancreatic neuroendocrine tumors and potential clinical applications.

Ban X, Mo S, Lu Z, Jia C, Shao H, Chang X Endocrine. 2022; 77(3):538-545.

PMID: 35708896 DOI: 10.1007/s12020-022-03102-y.

References

Furukawa M, Raffeld M, Mateo C, Sakamoto A, Moody T, Ito T . Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases. Clin Cancer Res. 2005; 11(9):3233-42. DOI: 10.1158/1078-0432.CCR-04-1915. View

Heinrich M, Corless C, Demetri G, Blanke C, von Mehren M, Joensuu H . Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003; 21(23):4342-9. DOI: 10.1200/JCO.2003.04.190. View

Amado R, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman D . Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26(10):1626-34. DOI: 10.1200/JCO.2007.14.7116. View

Corless C, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P . PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005; 23(23):5357-64. DOI: 10.1200/JCO.2005.14.068. View

Paez J, Janne P, Lee J, Tracy S, Greulich H, Gabriel S . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676):1497-500. DOI: 10.1126/science.1099314. View

Perez E, Roche P, Jenkins R, Reynolds C, Halling K, Ingle J . HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc. 2002; 77(2):148-54. DOI: 10.4065/77.2.148. View

Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F . Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005; 6(5):279-86. DOI: 10.1016/S1470-2045(05)70102-9. View

Lynch T, Bell D, Sordella R, Gurubhagavatula S, Okimoto R, Brannigan B . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350(21):2129-39. DOI: 10.1056/NEJMoa040938. View

Cappuzzo F, Varella-Garcia M, Shigematsu H, Domenichini I, Bartolini S, Ceresoli G . Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol. 2005; 23(22):5007-18. DOI: 10.1200/JCO.2005.09.111. View

10.

Rinke A, Muller H, Schade-Brittinger C, Klose K, Barth P, Wied M . Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009; 27(28):4656-63. DOI: 10.1200/JCO.2009.22.8510. View

11.

Raymond E, Dahan L, Raoul J, Bang Y, Borbath I, Lombard-Bohas C . Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):501-13. DOI: 10.1056/NEJMoa1003825. View

12.

Papouchado B, Erickson L, Rohlinger A, Hobday T, Erlichman C, Ames M . Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol. 2005; 18(10):1329-35. DOI: 10.1038/modpathol.3800427. View

13.

Kaku M, Nishiyama T, YAGAWA K, Abe M . Establishment of a carcinoembryonic antigen-producing cell line from human pancreatic carcinoma. Gan. 1980; 71(5):596-601. View

14.

Cappuzzo F, Finocchiaro G, Rossi E, Janne P, Carnaghi C, Calandri C . EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol. 2007; 19(4):717-23. DOI: 10.1093/annonc/mdm492. View

15.

Kulke M, Hornick J, Frauenhoffer C, Hooshmand S, Ryan D, Enzinger P . O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res. 2009; 15(1):338-45. PMC: 3100724. DOI: 10.1158/1078-0432.CCR-08-1476. View

16.

Karapetis C, Khambata-Ford S, Jonker D, OCallaghan C, Tu D, Tebbutt N . K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359(17):1757-65. DOI: 10.1056/NEJMoa0804385. View

17.

Eberhard D, Johnson B, Amler L, Goddard A, Heldens S, Herbst R . Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005; 23(25):5900-9. DOI: 10.1200/JCO.2005.02.857. View

18.

Massarelli E, Varella-Garcia M, Tang X, Xavier A, Ozburn N, Liu D . KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res. 2007; 13(10):2890-6. DOI: 10.1158/1078-0432.CCR-06-3043. View

19.

Yao J, Shah M, Ito T, Bohas C, Wolin E, Van Cutsem E . Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):514-23. PMC: 4208619. DOI: 10.1056/NEJMoa1009290. View

20.

Cory A, Owen T, BARLTROP J, CORY J . Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun. 1991; 3(7):207-12. DOI: 10.3727/095535491820873191. View